Thomas G. Martin, MD
Autologous stem cell transplantation (ASCT) continues to have an imperative role in the multiple myeloma paradigm, as most patients with the disease are able to tolerate it and it is a go-to strategy for physicians, explained Thomas G. Martin, MD.
State of the Science Summit™ on Hematologic Malignancies, Martin, associate director of the Myeloma Program at the University of California, San Francisco, discussed the clinical utility of ASCT and the rapidly evolving treatment paradigm of myeloma.
OncLive: Please provide an overview of your presentation.
: There are some limitations to ASCT. Patients older than age 75 are rarely transplant candidates. I would say almost all patients younger than 70 are eligible candidates. Most of the patients, if they're ineligible, it's because they have ongoing pulmonary comorbidities or cardiac issues.
... to read the full story